Table 2 Association analysis of lncRNA-derived molecular subtypes with established somatic aberrations and other risk factors
From: Expression levels of long non-coding RNAs are prognostic for AML outcome
Cluster | G1 | G2 | G3 | G4 | p value | Adjusted p value |
|---|---|---|---|---|---|---|
Patients | 65 (23.72%) | 56 (20.44%) | 86 (31.39%) | 67 (24.45%) | ||
Mutation | ||||||
FLT3_ITD | 15(5.47%) | 12(4.38%) | 37(13.50%) | 4(1.46%) | 2.88E−06 | 3.60E−05 |
NPM1 | 18(6.57%) | 19(6.93%) | 40(14.60%) | 6(2.19%) | 1.09E−05 | 9.08E−05 |
TP53 | 5(1.82%) | 3(1.09%) | 3(1.09%) | 13(4.75%) | 3.95E−03 | 1.98E−02 |
KRAS | 3(1.09%) | 5(1.82%) | 0(0.00%) | 3(1.09%) | 5.81E−02 | 1.45E−01 |
IDH1 | 12(4.38%) | 2(0.73%) | 8(2.92%) | 6(2.19%) | 5.25E−02 | 1.45E−01 |
RUNX1 | 14(5.11%) | 7(2.56%) | 7(2.56%) | 11(4.01%) | 1.19E−01 | 2.70E−01 |
WT1 | 1(0.36%) | 1(0.36%) | 6(2.19%) | 1(0.36%) | 1.36E−01 | 2.83E−01 |
FLT3-TKD | 15(5.47%) | 15(5.47%) | 41(14.96%) | 6(2.19%) | 1.92E−06 | 3.60E−05 |
ASXL1 | 6(2.19%) | 8(2.92%) | 5(1.82%) | 9(3.29%) | 3.02E−01 | 4.19E−01 |
CEBPA | 11(4.01%) | 6(2.19%) | 15(5.47%) | 7(2.56%) | 4.82E−01 | 5.48E−01 |
CEBPA (double) | 4(1.46%) | 1(0.36%) | 8(2.92%) | 4(1.46%) | 3.63E−01 | 4.78E−01 |
IDH2 | 16(5.84%) | 9(3.29%) | 16(5.84%) | 9(3.29%) | 3.93E−01 | 4.91E−01 |
TET2 | 14(5.11%) | 16(5.84%) | 21(7.66%) | 11(4.01%) | 4.22E−01 | 5.02E−01 |
DNMT3A | 16(5.84%) | 14(5.11%) | 17(6.20%) | 16(5.84%) | 8.59E−01 | 8.67E−01 |
Cytogenetic aberrations | ||||||
Normal karyotype | 36(13.79%) | 31(11.88%) | 45(17.24%) | 18(6.90%) | 3.96E−03 | 1.98E−02 |
inv(16)/t(16;16) | 0(0.00%) | 2(0.77%) | 1(0.38%) | 6(2.30%) | 9.05E−03 | 3.23E−02 |
del5 | 5(1.92%) | 2(0.77%) | 1(0.38%) | 9(3.45%) | 7.85E−03 | 3.23E−02 |
del7 | 7(2.68%) | 1(0.38%) | 7(2.68%) | 12(4.60%) | 1.53E−02 | 4.78E−02 |
t(8;21) | 0(0.00%) | 1(0.38%) | 1(0.38%) | 3(1.15%) | 2.32E−01 | 3.75E−01 |
+ 8 | 2(0.77%) | 5(1.92%) | 4(1.53%) | 7(2.68%) | 2.40E−01 | 3.75E−01 |
t(11q23) | 0(0.00%) | 3(1.15%) | 2(0.77%) | 2(0.77%) | 2.94E−01 | 4.19E−01 |
t(15;17) | 3(1.15%) | 1(0.38%) | 4(1.53%) | 1(0.38%) | 6.60E−01 | 7.17E−01 |
inv(3)/t(3;3) | 1(0.38%) | 1(0.38%) | 1(0.38%) | 2(0.77%) | 8.67E−01 | 8.67E−01 |
ELN risk | ||||||
High | 16(6.15%) | 10(3.85%) | 16(6.15%) | 21(8.08%) | 2.11E−01 | 3.75E−01 |
Intermediate | 37(14.23%) | 32(12.31%) | 53(20.39%) | 27(10.38%) | ||
Low | 9(3.46%) | 13(5.00%) | 14(5.38%) | 12(4.62%) | ||
Etiology | ||||||
De novo | 48(17.65%) | 45(16.54%) | 73(26.84%) | 56(20.59%) | 1.52E−01 | 2.92E−01 |
s-AML | 4(1.47%) | 4(1.47%) | 8(2.94%) | 8(2.94%) | ||
t-AML | 11(4.04%) | 7(2.57%) | 5(1.84%) | 3(1.10%) | ||